Herantis Pharma's Phase 2 Dry Eye study recruitment

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Herantis Pharma's Phase 2 Dry Eye study recruitment completed ahead of schedule

Herantis Pharma's Phase 2 Dry Eye study recruitment completed ahead of schedule Herantis Pharma Plc Company release 11 March 2015 at 10:00 am Herantis Pharma Plc has completed patient recruitment in its Phase 2 clinical study ahead of schedule. Also the number of recruited patients exceeded targets: A total of 161 patients were randomized in the study compared to the targeted 150 patients. The randomized patients will receive 4 weeks of treatment with either placebo eye drops or either of two different strengths of cis-UCA Eye Drops. The objective of the study is to compare the safety and efficacy of Cis- UCA Eye Drops to placebo, for the treatment of the signs and symptoms of Dry Eye Syndrome. This study is conducted in the USA by Ora, Inc., the world's leading independent, full-service ophthalmic clinical research and product development firm. "The study has proceeded extremely well", appreciates Pekka Simula, CEO of Herantis. "Thanks to our seamless long-time collaboration and the experience of Ora in this field the patient recruitment exceeded our expectations both in terms of schedule and the number of patients randomized. A higher number of patients means stronger statistical significance of the results, which is a critical factor in this business." "This is a data driven industry", reminds Burkhard Blank, MD, Herantis' Chief Medical Officer. "We really look forward to the results of this study as they will eventually tell us whether our cis-UCA Eye Drops work for the treatment of Dry Eye, as we have a reason to believe based on preclinical efficacy data." Herantis Pharma intends to publish top-line data of the Phase 2 study during the second quarter of 2015. The company had previously estimated that top-line results would be announced by September 2015. If the results of the study are positive the company aims to proceed toward commercialization of cis-UCA Eye Drops for instance by negotiating a commercialization agreement with a global pharmaceutical company. Further information: Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445 Company web site: www.herantis.com Certified Advisor: UB Capital Oy, telephone: +358 9 2538 0225 About Dry Eye Syndrome Dry Eye Syndrome (Keratoconjunctivitis sicca) is the most common cause of irritation in the eye. Typical subjective symptoms include dryness, burning sensation, pain, redness, and feeling of dirt in the eye. A severe or prolonged Dry Eye Syndrome may lead to complications causing damage to the surface of the eye and impaired vision. Dry Eye Syndrome is expected to become more prevalent with the aging population and with increasing use of computers and mobile devices. About Cis-UCA Eye Drops Cis-UCA Eye Drops is an ophthalmic solution indicated for the treatment of the signs and symptoms of Dry Eye Syndrome. Cis-urocanic acid (Cis-UCA), the active product ingredient of Cis-UCA Eye Drops, is an endogenous small molecule component of human and animal skin. It is constantly present in the human body and has been identified as a locally acting anti-inflammatory agent, which also reduces free radicals. Cis-UCA Eye Drops has previously been investigated in an experimental model of dry eye in the mouse, to simulate the Phase 2 clinical study. The results indicate that 1% Cis-UCA Eye Drops is efficacious in reducing corneal fluorescein staining in the model and performs better than the clinical comparator, Restasis®. The reported sales of Restasis® in 2014 exceeded 1 billion US dollars. About drug development Drug development projects can usually be divided in two stages: The preclinical stage, and the clinical stage involving human subjects. The clinical stage can be further broken in three formal phases. Phase 1 clinical studies assess the safety of a drug candidate in human subjects. In Phase 2, the optimal dosing and possible efficacy in the treatment of a particular disease is studied. Phase 3 studies finally aim to establish a statistical proof of safety and efficacy of the drug candidate in typically hundreds or thousands of patients for market approval. Drug development can take 10-15 years from the first preclinical studies to market approval. About Herantis Pharma Plc Herantis Pharma Plc is a pharmaceutical company specialised in new drug research and development. The company focuses on diseases with an unmet clinical need. These diseases include for example dry eye syndrome, Parkinson's disease, and secondary lymphedema. We believe our drugs are the first or best in their class and have the potential to change treatment strategies of diseases. The shares of Herantis Pharma Plc are listed on the First North Finland marketplace run by NASDAQ Helsinki stock exchange. [HUG#1900318]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 56

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage

Updated Category News Views 158

Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 114

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 114

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 82

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Physiatry or Orthopedics: Sorting Out Pain Care Choices

Updated Category News Views 47

Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 117

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 220

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes

Updated Category News Views 22

A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 177

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading

Top 5 Most Recently Viewed Articles

Impact of Withdrawal on Menthol Cigarette Regulation Efforts

Updated Category News Views 158

The Trump Administration's Recent Decision Recently, the Trump administration made headlines by withdrawing a previously proposed ban on menthol cigarettes in the United States. This decision marks a significant setback for health regulators and activists who have long been advocating for healthier tobacco policies. Background of the Proposal In April 2022, the Food and...

Continue Reading
Carta Healthcare Secures Gold by Innovating Clinical Data

Updated Category News Views 18

Tackling a Stubborn Healthcare Pain Point Let's face it: the healthcare industry's data management game has been sweating buckets over a Herculean task for years. A staggering $10-15 billion gets burned annually thanks to inefficient clinical data abstraction. Today's hero of this tale? Carta Healthcare, which just snagged a shining Gold at the 2026 Stevie Awards in...

Continue Reading
SentinelOne Earns Prestigious Recognition from Gartner for 2024

Updated Category News Views 456

SentinelOne's Recent Achievement in Cloud Security SentinelOne (NYSE: S), a prominent player in the field of AI-driven security solutions, has recently been acknowledged as a Customers' Choice in the 2024 Gartner® Peer Insights™ report specifically for Cloud-Native Application Protection Platforms. This recognition reflects feedback from a broad user base, emphasizing...

Continue Reading
Tingus Goose: A Premium Idle Game Experience on Steam

Updated Category News Views 201

Exciting Announcement for Gamers The cult phenomenon, Tingus Goose, is making its debut on Steam as a fully enhanced 1.0 edition designed for PC players. Co-published by Playsaurus and Ultraplayers, this adaptation aims to deliver the ultimate idle gaming experience, free from the distractions found in mobile versions. What’s New in Tingus Goose? Unique Gameplay...

Continue Reading
TrackerRMS Launches Innovative Onboarding+ Solution for Staffing

Updated Category News Views 368

Introducing the New Onboarding+ Solution by TrackerRMS TrackerRMS has taken a significant step in revolutionizing the recruitment landscape with the introduction of its Onboarding+ solution. This innovative tool is designed specifically for recruitment agencies looking to enhance their onboarding process and improve the overall candidate journey. By integrating advanced...

Continue Reading